196 related articles for article (PubMed ID: 27899803)
1. Novel targets in the treatment of chronic graft-versus-host disease.
Im A; Hakim FT; Pavletic SZ
Leukemia; 2017 Mar; 31(3):543-554. PubMed ID: 27899803
[TBL] [Abstract][Full Text] [Related]
2. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
[TBL] [Abstract][Full Text] [Related]
3. Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
Pidala J
Cancer Control; 2011 Oct; 18(4):268-76. PubMed ID: 21976245
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Al-Homsi AS; Feng Y; Duffner U; Al Malki MM; Goodyke A; Cole K; Muilenburg M; Abdel-Mageed A
Exp Hematol; 2016 Sep; 44(9):771-777. PubMed ID: 27224851
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
De Togni E; Cole O; Abboud R
Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
[TBL] [Abstract][Full Text] [Related]
7. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
8. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
[TBL] [Abstract][Full Text] [Related]
10. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
[TBL] [Abstract][Full Text] [Related]
11. Current and novel therapies in acute GVHD.
Ho VT; Cutler C
Best Pract Res Clin Haematol; 2008 Jun; 21(2):223-37. PubMed ID: 18503988
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].
Martínez C
Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():69-71. PubMed ID: 21381292
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.
Nakasone H; Sahaf B; Miklos DB
Int J Hematol; 2015 May; 101(5):438-51. PubMed ID: 25812839
[TBL] [Abstract][Full Text] [Related]
14. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
15. Regulatory B10 cells display an altered homoeostasis in acute graft-versus-host disease.
Chakupurakal G; Garcia-Marquez MA; Shimabukuro-Vornhagen A; Kluth S; Schlosser H; Theurich S; Scheid C; Hallek M; Holtick U; von Bergwelt-Baildon M
Eur J Haematol; 2017 Feb; 98(2):128-133. PubMed ID: 27717015
[TBL] [Abstract][Full Text] [Related]
16. Advances in understanding the pathogenesis of graft-versus-host disease.
Magenau J; Runaas L; Reddy P
Br J Haematol; 2016 Apr; 173(2):190-205. PubMed ID: 27019012
[TBL] [Abstract][Full Text] [Related]
17. Kinase Inhibition as Treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract][Full Text] [Related]
18. Recognizing and managing chronic graft-versus-host disease.
Lee SJ; Flowers ME
Hematology Am Soc Hematol Educ Program; 2008; ():134-41. PubMed ID: 19074071
[TBL] [Abstract][Full Text] [Related]
19. Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.
Al-Homsi AS; Goodyke A; McLane M; Abdel-Mageed S; Cole K; Muilenburg M; Feng Y
Biol Blood Marrow Transplant; 2017 Feb; 23(2):255-261. PubMed ID: 27888016
[TBL] [Abstract][Full Text] [Related]
20. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.
Kasikis S; Etra A; Levine JE
BioDrugs; 2021 Jan; 35(1):19-33. PubMed ID: 33201499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
